Breast Cancer Now media statements
Breast Cancer Now welcomes NICE approval of abemaciclib with fulvestrant for routine use on the NHS
The National Institute for Health and Care Excellence (NICE) has today announced its decision to approve abemaciclib with fulvestrant for ro...
We respond to a new study into the use of ErSO to shrink oestrogen receptor positive breast cancer in mice
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
We respond to announcement from NHS England of a new Innovative Medicines Fund
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, responded to the announcement from NHS England of a new Innovative Medicines F...
We respond to the latest census of clinical oncologists from The Royal College of Radiologists
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, responded to the latest census of clinical oncologists from The Royal College ...
We welcome new treatment method for HER2 positive breast cancer for use on Scotland’s NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to NHS England breast cancer waiting times: May 2021
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to new research into fertility drugs and breast cancer risk
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
We respond to POLQ inhibitors identified as a new class of targeted drugs for cancers with BRCA mutations
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
We respond to new figures from Cancer Research UK showing thousands fewer breast cancer patients started treatment in the last year in England
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to a new clinical trial into olaparib use for women with high risk HER2 negative primary breast cancer with altered BRCA genes
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
We respond to government funding announcement for early career researchers supported by charities
Responding to the Department for Business, Energy and Industrial Strategy's (BEIS) announcement of funding for early career researchers supp...
We respond to the announcement of more than £25m being invested in diagnostic equipment for NHS Wales
Mia Rosenblatt, Associate Director of Evidence, Policy and Influencing at Breast Cancer Now, said: